which as you pointed out in a post that was deleted, REDUCE-IT showed that Vascepa did not show a statistically significant benefit in the primary prevention population. While you are correct that,
Amarin is not asking for a label for that specific population. If they had, the FDA would have asked for primary prevention trial in that population.
Bringing it back to the issue at hand, the FDA would have been well within their means to ask for a primary prevention trial for the indication that Amarin proposed in there application, however, the agency decided to defer to an advisory committee instead.